Semaglutide, the active ingredient in brands like Ozempic and Wegovy, is a glucagon-like peptide 1 (GLP-1) receptor agonist with the following benefits: Controls blood sugar Encourages weight loss Emulates the natural GLP-1 hormone Triggers insulin production Stifles glucagon release Decelerates gut movement Administered just once weekly, this medication became a game-changer, especially after its 2021 approval for weight loss under the brand name Wegovy
Newer agents like survodutide , orforglipron , or mazdutide are in various stages of development and clinical use, and retatrutide (a triple agonist targeting GIP, GLP-1, and glucagon receptors) shows even greater weight loss potential than tirzepatide in early trials
It is a key player in the formation of red blood cells, responsible for carrying oxygen throughout the body
ClinicalTrials.gov SURMOUNT-1 - Tirzepatide Once Weekly in Adults with Obesity
By enrolling in this course, you will not only expand your aesthetic clinics range of services, but also boost your business and attract more clients
As research continues to evolve, healthcare providers can help patients understand current evidence, limitations, and appropriate clinical considerations